Novo Nordisk A/S $NVO Shares Bought by American Century Companies Inc.

Key Points

• American Century Companies increased its stake in Novo Nordisk by 4.2% to 771,591 shares (worth about $42.8M), while other institutions like SG Americas and DAVENPORT & Co. also made large additions, with institutional investors owning roughly 11.54% of the stock.
• Analysts give NVO a consensus rating of "Hold" with a consensus target price of $53.93 (5 Buy, 17 Hold, 1 Sell), and recent notable calls include a Deutsche Bank downgrade and TD Cowen reissuing a Buy.
• Novo Nordisk beat Q results (EPS $1.01 vs. $0.90 consensus; revenue $12.43B) and announced a $1.2751 dividend payable April 8 (record March 30), but the stock slid ~1.2% amid competitive and regulatory risks such as Roche’s obesity drug progress, potential low‑cost generics, FDA advertising warnings, and an investor investigation.

American Century Companies Inc. raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 771,591 shares of the company's stock after buying an additional 30,936 shares during the period. American Century Companies Inc.'s holdings in Novo Nordisk A/S were worth $42,816,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. SG Americas Securities LLC grew its holdings in Novo Nordisk A/S by 2,101.5% in the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company's stock valued at $132,242,000 after buying an additional 2,274,925 shares in the last quarter. DAVENPORT & Co LLC increased its position in Novo Nordisk A/S by 54.8% during the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company's stock worth $146,644,000 after purchasing an additional 935,468 shares during the last quarter. Sustainable Growth Advisers LP raised its stake in Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company's stock worth $427,416,000 after purchasing an additional 649,390 shares during the period. Baird Financial Group Inc. increased its stake in Novo Nordisk A/S by 42.6% during the second quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company's stock worth $101,920,000 after acquiring an additional 441,034 shares during the last quarter. Finally, Holocene Advisors LP acquired a new stake in Novo Nordisk A/S during the second quarter worth $25,745,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the subject of a number of recent analyst reports. HSBC reiterated a "hold" rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, February 23rd. Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, February 5th. Argus reiterated a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, TD Cowen reissued a "buy" rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Five analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $53.93.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised Novo Nordisk to Equal Weight, and related analyst chatter lifted the stock in earlier trading — a near-term supportive catalyst. Novo Nordisk A/S NYSE: NVO Raised to Equal Weight at Morgan Stanley
• Neutral Sentiment: General coverage and “trending” write-ups (Zacks/Yahoo) are driving retail attention but contain no new fundamental news; these pieces can increase volume/volatility without changing long‑term fundamentals. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Be aware of ticker-noise: several press releases referencing “NVO” (Novo Resources, ASX: NVO) circulated today — these are not related to Novo Nordisk NYSE: NVO but can create confusion in scanners and newsfeeds. Completion of Tranche 1 of Placement and Valuation Update
• Negative Sentiment: Roche reported positive Phase II results for petrelintide (up to ~10.7% weight loss with good tolerability) and plans further development — new obesity competitors gaining efficacy/tolerability could pressure Novo Nordisk’s market share and growth expectations. Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
• Negative Sentiment: A study reporting generic Ozempic/Wegovy could be produced for under $3/month highlights potential long‑term pricing pressure and margin risk if cheaper biosimilars/generics scale globally. That raises erosion risk to high-margin GLP‑1 revenues. Generic Ozempic Could Cost Less Than $3 a Month, Study Shows
• Negative Sentiment: Regulatory scrutiny increased after the FDA issued (another) warning about marketing/ads for Ozempic/Wegovy — ongoing ad/regulatory issues could hurt promotion and patient uptake and lead to fines or stricter controls. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: Pomerantz law firm announced an investigation into Novo Nordisk investor claims, which can increase legal uncertainty and weigh on sentiment until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

Novo Nordisk A/S Stock Down 1.2%

Shares of NYSE NVO opened at $38.60 on Friday. The stock has a market capitalization of $172.35 billion, a price-to-earnings ratio of 11.12 and a beta of 0.73. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $88.55. The firm has a 50-day moving average price of $51.41 and a 200 day moving average price of $52.38. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S's payout ratio is currently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.